Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 2011. The report details a specific share repurchase transaction executed on March 16, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 6, 2010.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,600,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,156 pence per share; lowest price paid was 1,144.50 pence per share.
- Treasury Holdings (Settled): 490,254,284 shares (8.64% of total issued share capital).
- Treasury Holdings (Including Unsettled): 493,224,284 shares (9.52% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,180,820,675 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 1,600,000 shares on March 16, 2011. These shares are intended to be held in Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 9.52% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The document is a procedural notification of a share repurchase and the resulting capital structure.
Investor Verification Checklist
- Verify the total cost of the 1,600,000 shares purchased using the reported price range (1,144.50 to 1,156 pence).
- Confirm the impact of the 9.52% Treasury holding on the denominator for shareholder notification thresholds under the Financial Services Authority's Disclosure and Transparency Rules.
- Check subsequent filings for the settlement status of the shares included in the "unsettled" count.